ASCO GI Studies to Monitor

At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Christopher Lieu, MD, of University of Colorado Medicine, details three studies of practice-changing importance to keep an eye on.

He breaks down the expanded analyses of CheckMate-9DW, BREAKWATER in BRAF V600E-mutant metastatic colorectal cancer, and the first results of nivolumab plus ipilimumab vs nivolumab monotherapy for MSI-H/dMMR metastatic colorectal cancer from CheckMate 8HW.